Month: March 2024

2071 posts
Techtouch, Inc. ranks 8th in Technology Fast 50 2023 Japan, a ranking of fastest growing technology companies, with a 468.6% revenue growth rate

Techtouch, Inc. ranks 8th in Technology Fast 50 2023 Japan, a ranking of fastest growing technology companies, with a 468.6% revenue growth rate

TOKYO, March 29, 2024 /PRNewswire/ — Techtouch, Inc. (Headquarter: Tokyo, Japan, President/CEO: Naka…
Jacobio Pharma Announces 2023 Annual Results

Jacobio Pharma Announces 2023 Annual Results

BEIJING, SHANGHAI and BOSTON, March 29, 2024 Jacobio/PRNewswire/ —  Pharma (1167.HK), a…
Xinhua Silk Road: E. China's Shandong Zaozhuang greets tourists with spring blossoms

Xinhua Silk Road: E. China's Shandong Zaozhuang greets tourists with spring blossoms

BEIJING, March 29, 2024 /PRNewswire/ — Zaozhuang City of east China’s Shandong…
Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages

Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages

HONG KONG, March 29, 2024 /PRNewswire/ — "We are even more clear…
Music China Returns in 2024 with Enhanced Quality Boosted by UFI Certification

Music China Returns in 2024 with Enhanced Quality Boosted by UFI Certification

SHANGHAI, March 29, 2024 /PRNewswire/ — Music China will come back on…
Quhuo to Report Unaudited Financial Results for the Second Half and Full Year 2023 on April 3, 2024

Quhuo to Report Unaudited Financial Results for the Second Half and Full Year 2023 on April 3, 2024

BEIJING, March 29, 2024 /PRNewswire/ — Quhuo Limited (NASDAQ: QH) ("Quhuo," the "Company,"…
JUMBO Group Launches JUMBO Academy to Nurture Future F&B Professionals in Singapore

JUMBO Group Launches JUMBO Academy to Nurture Future F&B Professionals in Singapore

To address the issue of talent shortage in Singapore’s F&B industry, JUMBO…
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade

Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade

SEONGNAM, South Korea and ATLANTA, March 29, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a…